Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26190903 | 1.00 | POLB (0.39) | POLBKDM4EP2RY1POLA1TYMP | |
| SCHEMBL21489241 | 1.00 | POLB (0.39) | POLBKDM4EP2RY1POLA1TYMP | |
| SCHEMBL21489385 | 0.91 | POLB (0.48) | POLBSTING1P2RY2P2RY4P2RY6 | |
| SCHEMBL21489244 | 0.91 | POLB (0.39) | POLBKDM4EP2RY1POLA1TYMP | |
| SCHEMBL21473301 | 0.91 | POLB (0.48) | POLBSTING1P2RY2P2RY4P2RY6 | |
| SCHEMBL21474252 | 0.88 | KDM4E (0.39) | POLBKDM4EP2RY1POLA1TYMP | |
| SCHEMBL26189244 | 0.86 | POLB (0.43) | POLBKDM4EPOLA1TYMPSTING1 | |
| SCHEMBL21504648 | 0.85 | IMPDH2 (0.42) | STING1IMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL21489257 | 0.85 | IMPDH2 (0.42) | STING1IMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL21489355 | 0.83 | STING1 (0.45) | STING1IMPDH2IMPDH1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-24 | — | — | US | disclosed |
| WO-2019200273-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | POLB 2210/4885KDM4E 2416/4885P2RY1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.